China Biologic Products (NASDAQ:CBPO) ($53.09) – a leading fully integrated plasma-based biopharmaceutical company in China, today announced :

completed the transaction to acquire an additional 19.84% equity interest in Guizhou Taibang Biological Products Co., Ltd (“Guizhou Taibang”) and increased its registered equity interests in Guizhou Taibang from 56.39% to 76.23%.